CBIO · Crescent Biopharma, Inc.
AI read · Good for CBIO
The AI's read
This gives Crescent more ways to test its cancer drugs and keeps several programs moving toward planned patient updates. The FDA has allowed CR-002 to proceed, and CR-001 has finished dose increases in its first study. But the filing reports trial activity and future timelines, not proof that the drugs help patients. Plans for later CR-001 trials also depend on study results and talks with regulators.